Cormorant Asset Management »

Cg Oncology shares owned by Cormorant Asset Management

Quarter-by-quarter ownership of Cg Oncology shares owned by Cormorant Asset Management from 13F filings

Historical chart of Cormorant Asset Management investment in Cg Oncology

Tip: Access up to 7 years of quarterly data

All positions including Cg Oncology held by Cormorant Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Cg Oncology by Cormorant Asset Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $35M 800k 43.90

More positions owned by Cormorant Asset Management

Moonlake Immunotherapeutics Class A Ord (MLTX)
Eyepoint Pharmaceuticals Com New (EYPT)
Arcellx Common Stock (ACLX)
Alpine Immune Sciences (ALPN)
Bridgebio Pharma (BBIO)
Praxis Precision Medicines I Com New (PRAX)
Corbus Pharmaceuticals Hldgs Com New (CRBP)
Tarsus Pharmaceuticals (TARS)
Longboard Pharmaceuticals In (LBPH)
Edgewise Therapeutics (EWTX)
Crinetics Pharmaceuticals In (CRNX)
Biomea Fusion (BMEA)
Korro Bio (KRRO)
Vaxcyte (PCVX)
Autolus Therapeutics Spon Ads (AUTL)

View all positions for Cormorant Asset Management

Top funds holding Cg Oncology

BlackRock
Vanguard Group
BVF
Henderson Group
Avidity Partners Management
RA Capital Management
Perceptive Advisors
Braidwell
T. Rowe Price Associates
Franklin Resources
Cormorant Asset Management
Frazier Life Sciences Management
Holocene Advisors
T. Rowe Price Investment Management
Foresite Capital Management V

View all funds holding Cg Oncology